---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-100076"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:22:36.408458+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CVRx Q2 revenue up 150% to $3.1M; IPO nets $133.3M

## Summary
- Total revenue $3.1M (+150% YoY); U.S. HF revenue $2.0M (from $65K).
- Net loss $17.7M (incl. $11.4M non-cash warrant expense); cash $47.1M.
- IPO closed July 2; net proceeds ~$133.3M; 8.05M shares at $18.
- Full-year 2021 revenue guidance $13.3-13.9M; Q3 revenue $3.3-3.6M.
- Active implanting centers increased to 31; Martha Shadan appointed; first BATwire procedure performed.

## SEC filing metadata
- accession: 0001104659-21-100076
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465921100076/0001104659-21-100076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465921100076/tm2123927d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-100076
- JSON: https://secwatch.observer/filing/0001104659-21-100076.json
- Plain text: https://secwatch.observer/filing/0001104659-21-100076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.